MedLumics, S.L.

MedLumics, S.L. is a medical device company based in Madrid, Spain, founded in 2009. The company specializes in designing and developing catheter-based systems for cardiac care, particularly targeting the treatment of atrial fibrillation (AF). MedLumics is known for its pioneering work in biophotonics technology, which enhances real-time visualization of heart tissue during cardiac ablation procedures. The flagship product, the AblaView® Unipolar Hybrid System, is an optically guided radiofrequency ablation catheter system. This innovative system allows clinicians to visualize and assess the positioning of the ablation catheter on the myocardium, improving the precision and safety of cardiac ablations. MedLumics aims to enhance patient outcomes and procedural efficiency through its advanced technology. The company also envisions expanding its applications to other areas of cardiac care and integrating artificial intelligence into its solutions. With a strong patent portfolio and state-of-the-art laboratory facilities, MedLumics collaborates with a network of industrial, scientific, and clinical partners. The company has successfully secured multiple funding rounds, including a €14 million Series E round in 2020 and an €18 million round in 2021, to support its growth and innovation in the medical device sector.

• Employees 25
• Founded 2014
• Annual Revenue $7000000
• Total Funding $79927267